Safety Considerations When Combining Metformin with GLP-1 Therapy The primary safety consideration involves gastrointestinal side effects, which occur more frequently when GLP-1 medications are introduced, particularly nausea and constipation during dose escalation phases
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB, PIONEER 7 investigators
Cell 25, 635646
Another GLP-1 agonist, Mounjaro, is prescribed by general practitioners in England for people with a BMI of 40 or higher (or 37.5 if from a minority ethnic background) who also have four out of five conditions (type 2 diabetes, high blood pressure, heart and vascular disease, high cholesterol, and obstructive sleep apnoea)
With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials addressing both the clinical realities of obesity and the practical challenges patients face every day, Horn noted